[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mastalgia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mastalgia":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,55,83,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100640820","phase-1-hormones-outcomes-and-pain-pathways-in-exercise-study-100640820",false,"NCT07579182","Hormones, Outcomes, and Pain Pathways in Exercise Study","Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women","HOPE","Inclusion Criteria:\n\n1. Able to provide informed consent\n2. Age of 18 to 60 years\n3. Assigned female sex at birth\n4. Right-handed by self-declaration\n5. Willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size between 32-40\"\n7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher\n8. An answer of \"NO\" to any item of the general health questions of the PARQ+\n9. No history of surgery to the: back, neck, or shoulders or joint replacement\n10. No history of implanted pacemakers or other stimulation devices\n11. No history of spinal cord injury (SCI)\n\nExclusion Criteria:\n\n1. Inability to provide informed consent\n2. Age 17 years old or younger or 61 years or older\n3. Assigned male sex at birth\n4. Left-handed by self-declaration\n5. Not willing to participate in one online testing session and up to four in-person testing sessions\n6. Bra band size greater than 40\" or less than 32\"\n7. IPAQ-SF score of 1 or lower\n8. An answer of \"YES\" to any item of the general health questions of the PARQ+\n9. History of limb amputation (upper or lower extremity)\n10. Presence of open pressure sores on the upper or lower extremities\n11. Currently pregnant or lactating\u002Fbreastfeeding\n12. History of surgery to the: back, neck, or shoulders or joint replacement\n13. History of breast cancer and\u002For mastectomy\n14. History of implanted pacemakers or other stimulation devices\n15. History of spinal cord injury (SCI)\n16. History of joint disease including osteoarthritis and\u002For Rheumatoid Arthritis\n17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and\u002For Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies\n\nAdditional Inclusion Criteria for Intervention Group:\n\na. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)\n\nAdditional Inclusion Criteria for the Control Group:\n\na. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)",true,"FEMALE","18 Years","60 Years",{"count":22,"type":23},140,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.",[29,30,31,32,33,34,35,36,37,38,39,40,41],"Breast Pain","Mastalgia","Back Pain","Back Pain, Low","Neck Pain","Chest Pain","Activity, Motor","Healthy Aging","Weight, Body","Inflammation","Gonadal Steroid Hormones","Neuronal Plasticity","Neuromuscular Manifestations","RECRUITING","2026-05-28",{"date":45,"type":46},"2026-06-02","ACTUAL",{"date":48,"type":46},"2026-05-17",{"date":50,"type":23},"2029-09",{"name":52,"class":53},"University of Houston","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":24,"phases":65,"briefSummary":67,"conditions":68,"keywords":69,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":54},"100612760","local-treatment-of-breast-pain-based-on-the-daily-use-of-a-topical-gel-100612760","NCT07257770","Local Treatment of Breast Pain Based on the Daily Use of a Topical Gel","Evaluating the Effect of a Medical Device Based on Inositol in Improving Breast Pain","Inclusion Criteria:\n\n* Women aged between 18 and 70 years\n* Women who underwent breast surgery at least 15 days prior\n* Women experiencing breast pain associated with the surgical wound\n\nExclusion Criteria:\n\n* Women under the age of 18\n* Ongoing systemic and\u002For local pain therapy\n* Pregnant women","70 Years",{"count":64,"type":23},50,[66],"NA","The trial aims to investigate the effect of a topical application of a medical device based on inositol in recovering breast pain",[30],[70,71,72],"inositol","breast pain","mastalgia","2026-02-12",{"date":75,"type":46},"2026-02-13",{"date":77,"type":46},"2025-09-11",{"date":79,"type":23},"2026-07-11",{"name":81,"class":82},"Lo.Li.Pharma s.r.l","INDUSTRY",{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":54},"100590348","phase-3-external-mastalgia-oil-versus-placebo-in-premenopausal-women-with-severe-mastalgia-100590348","NCT06966245","External Mastalgia-oil Versus Placebo in Premenopausal Women With Severe Mastalgia","External Mastalgia-oil Versus Placebo in Premenopausal Women With Severe Mastalgia: a Double-blind, Randomized Clinical Trial","Inclusion Criteria:\n\n* Premenopausal females aged ≥ 18 years old\n* Pre-existing regular menstrual cycle (28 ± 5 days) with mastalgia lasting for at least 6 consecutive menstrual cycles; with severe mastalgia \\[visual analog scale (VAS) score ≥ 4 for at least 7 days\\] and without chest wall pain in the baseline menstrual cycle (nonmedicated menstrual cycle)\n* With breast ultrasound: BI-RADS classification 1-3; if mammography is required: also BI-RADS classification 1-3\n* Willingness to follow up and complete required tests; ability to complete questionnaires independently or with assistance\n* Willingness to use effective contraception (vaginally administered estrogen and hormone-coated IUDs are permitted) prior to study entry, during study participation, and for three months after discontinuation of the drug; negative pregnancy test in females of childbearing potential\n* Requisite laboratory values:white blood cell count: ≥ 4.0 × 10\\^9\u002FL, absolute neutrophil count: ≥ 2 × 10\\^9\u002FL, platelet count: ≥ 100 × 10\\^9\u002FL; hemoglobin: ≥ 110 g\u002FL; aspartate aminotransferase and alanine aminotransferase: ≤ upper limit of normal, alkaline phosphatase: ≤ upper limit of normal, blood total bilirubin: ≤ upper limit of normal; serum creatinine and blood urea nitrogen: ≤ upper limit of normal\n\nExclusion Criteria:\n\n* With suspected breast disease (e.g., mastitis, malignant breast tumor) other than breast pain or benign breast cysts, or with other malignant tumors\n* Use of hormonal medications (e.g., oral contraceptives, glucocorticoids, etc.), sex hormone modulators (SERMS, AIs, SERDs, etc.), B vitamins, essential oils, nonsteroidal anti-inflammatory drugs, or higher pain relievers in the past 3 months; use of tamoxifen or analogs in the past 6 months\n* Prior history of breast surgery (including minimally invasive surgery), history of malignancy, or history of thromboembolism within the last 5 years (history of varicose veins and superficial phlebitis allowed)\n* Smokers; essential oils or placebo systemic\u002Fskin sensitization\n* With serious primary diseases of the heart, liver, kidneys and hematopoietic system, or mental illness, etc.\n* Accompanied by skin damage on the breast that destroys the stratum corneum (e.g., eczema, ulcers)\n* Serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to active hepatitis viral infection, human immunodeficiency virus antibody positivity, syphilis spirochete antibody positivity with evidence of active infection, and pulmonary infections\n* Subjects who are breastfeeding or pregnant at the time of screening (of childbearing age and with serum human chorionic gonadotropin test results higher than the reference value); subjects of childbearing age who have had unprotected sex with a heterosexual partner within 2 weeks prior to the screening; subjects of childbearing age who are planning to prepare for conception, become pregnant, breastfeed, or donate their eggs during the test period or within 3 months of the end of the test; and those with implanted breasts\n* Decrease in total breast pain score by more than 25% during the placebo lead-in cycle. These patients will not receive subsequent randomization and treatment.",{"count":91,"type":23},190,[93],"PHASE3","This is a single-center, double-blind, randomized clinical trial to explore the efficacy and safety of external mastalgia-oil versus placebo in premenopausal women with severe mastalgia.",[30],"2026-01-29",{"date":98,"type":46},"2026-02-02",{"date":100,"type":46},"2025-06-08",{"date":102,"type":23},"2027-12-01",{"name":104,"class":53},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":112,"targetDuration":4,"studyType":24,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":54},"100547192","phase-3-external-mastalgia-oil-versus-oral-tamoxifen-in-premenopausal-women-with-severe-mastalgia-100547192","NCT06404775","External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women with Severe Mastalgia","External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women with Severe Mastalgia: a Double-blind, Double-simulated, Positive-controlled Randomized Clinical Trial","Inclusion Criteria:\n\n* Premenopausal females aged ≥ 18 years old\n* Pre-existing regular menstrual cycle (28 ± 3 days) with mastalgia lasting for at least 6 consecutive menstrual cycles; with severe mastalgia \\[visual analog scale (VAS) score ≥ 4 for at least 7 days\\] and without chest wall pain in the baseline menstrual cycle (nonmedicated menstrual cycle)\n* With breast ultrasound: BI-RADS classification 1-3; if mammography is required: also BI-RADS classification 1-3\n* Willingness to follow up and complete required tests; ability to complete questionnaires independently or with assistance\n* Willingness to use effective contraception (vaginally administered estrogen and hormone-coated IUDs are permitted) prior to study entry, during study participation, and for three months after discontinuation of the drug; negative pregnancy test in females of childbearing potential\n* Requisite laboratory values:white blood cell count: ≥ 4.0 × 10\\^9\u002FL, absolute neutrophil count: ≥ 2 × 10\\^9\u002FL, platelet count: ≥ 100 × 10\\^9\u002FL; hemoglobin: ≥ 110 g\u002FL; aspartate aminotransferase and alanine aminotransferase: ≤ upper limit of normal, alkaline phosphatase: ≤ upper limit of normal, blood total bilirubin: ≤ upper limit of normal; serum creatinine and blood urea nitrogen: ≤ upper limit of normal\n\nExclusion Criteria:\n\n* With suspected breast disease (e.g., mastitis, malignant breast tumor) other than breast pain or benign breast cysts, or with other malignant tumors\n* Use of hormonal medications (e.g., oral contraceptives, glucocorticoids, etc.), sex hormone modulators (SERMS, AIs, SERDs, etc.), B vitamins, essential oils, nonsteroidal anti-inflammatory drugs, or higher pain relievers in the past 3 months; use of tamoxifen or analogs in the past 6 months\n* Prior history of breast surgery (including minimally invasive surgery), history of malignancy, or history of thromboembolism within the last 5 years (history of varicose veins and superficial phlebitis allowed)\n* Smokers; tamoxifen or essential oils systemic\u002Fskin sensitization\n* With serious primary diseases of the heart, liver, kidneys and hematopoietic system, or mental illness, etc.\n* Accompanied by skin damage on the breast that destroys the stratum corneum (e.g., eczema, ulcers)\n* Serious or uncontrolled infections that may interfere with study treatment or assessment of study results, including but not limited to active hepatitis viral infection, human immunodeficiency virus antibody positivity, syphilis spirochete antibody positivity with evidence of active infection, and pulmonary infections\n* Subjects who are breastfeeding or pregnant at the time of screening (of childbearing age and with serum human chorionic gonadotropin test results higher than the reference value); subjects of childbearing age who have had unprotected sex with a heterosexual partner within 2 weeks prior to the screening; subjects of childbearing age who are planning to prepare for conception, become pregnant, breastfeed, or donate their eggs during the test period or within 3 months of the end of the test; and those with implanted breasts\n* Decrease in total breast pain score by more than 25% during the placebo lead-in cycle. These patients will not receive subsequent randomization and treatment.",{"count":113,"type":23},456,[93],"This is a single-center, double-blind, double-simulated, positive-controlled, randomized clinical trial to explore the efficacy and safety of external mastalgia-oil versus oral tamoxifen in premenopausal women with severe mastalgia.",[30],"NOT_YET_RECRUITING","2024-11-26",{"date":120,"type":46},"2024-11-29",{"date":122,"type":23},"2025-01-16",{"date":124,"type":23},"2030-05-16",{"name":104,"class":53}]